In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) closed the day trading at $424.99 down -1.07% from the previous closing price of $429.60. In other words, the price has decreased by -$1.07 from its previous closing price. On the day, 1.63 million shares were traded.
Ratios:
For a better understanding of VRTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.29 and its Current Ratio is at 2.65. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.10.
On May 06, 2025, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform but kept the price unchanged to $503.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 02 ’25 when Bhatia Sangeeta N. sold 400 shares for $505.86 per share. The transaction valued at 202,344 led to the insider holds 4,831 shares of the business.
Bhatia Sangeeta N. bought 400 shares of VRTX for $202,344 on May 02 ’25. On Mar 13 ’25, another insider, ALTSHULER DAVID, who serves as the EVP, Chief Scientific Officer of the company, sold 3,231 shares for $510.00 each. As a result, the insider received 1,647,810 and left with 23,281 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 9.88 while its Price-to-Book (P/B) ratio in mrq is 6.62.
Stock Price History:
Over the past 52 weeks, VRTX has reached a high of $519.88, while it has fallen to a 52-week low of $377.85. The 50-Day Moving Average of the stock is -13.06%, while the 200-Day Moving Average is calculated to be -9.66%.
Shares Statistics:
A total of 256.97M shares are outstanding, with a floating share count of 256.04M. Insiders hold about 0.29% of the company’s shares, while institutions hold 93.56% stake in the company.
